NCT07243899 2025-11-24
Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy
Shanghai Zhongshan Hospital
Completed
Clinical Trials
27 trialsNCT05058560 2025-03-13
Tislelizumab in Addition to BACE in Patients with NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
NCT04691388 2024-12-05
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Zhejiang Cancer Hospital
Phase 2 Completed
NCT05383898 2024-10-15
Study to Evaluate D-1553 in Subjects With Lung Cancer
InventisBio Co., Ltd
Phase 1/2 Completed
NCT03810066 2024-05-09
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
University Hospital, Essen
Phase 2 Completed
NCT02869685 2024-02-23
RadImm02
Xinqiao Hospital of Chongqing
Phase NA Completed
NCT02890849 2024-02-23
RadImm01
Xinqiao Hospital of Chongqing
Phase NA Completed
NCT04204473 2023-11-18
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation
TYK Medicines, Inc
Phase 1 Completed
NCT03513666 2023-08-23
JS001
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Completed
NCT04871997 2022-10-21
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
Tongji Hospital
Completed
NCT03812809 2022-05-19
A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive
Beta Pharma, Inc.
Phase 2 Completed
NCT05034445 2021-09-05
Whether Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients With Lung Cancer
Guangzhou Institute of Respiratory Disease
Completed
NCT03394118 2021-04-27
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
Asan Medical Center
Phase 2 Completed
NCT04858204 2021-04-26
IMMUNOBZH
University Hospital, Brest
Completed
NCT02976116 2019-11-15
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT01859650 2019-09-26
HeXeRT
Sheffield Teaching Hospitals NHS Foundation Trust
Completed
NCT02029222 2019-09-04
Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.
Maastricht Radiation Oncology
Completed
NCT02691299 2019-02-12
FALUCA
Hutchmed
Phase 3 Completed
NCT03609918 2018-08-07
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Tianjin Medical University Cancer Institute and Hospital
Completed
NCT02315053 2017-10-27
PET Response During Chemoradiation of Lung Cancer
The Netherlands Cancer Institute
Phase NA Completed
NCT00874848 2016-11-29
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
HiberCell, Inc.
Phase 2 Completed
NCT00683514 2016-10-04
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT00259064 2016-06-02
INSTEP
AstraZeneca
Phase 2/3 Completed
NCT01769066 2016-02-23
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
Fudan University
Phase 2/3 Completed
NCT00655161 2014-01-29
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
GlobeImmune
Phase 2 Completed
NCT00298415 2013-10-25
Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Completed
NCT00072618 2011-10-20
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
Astellas Pharma Inc
Phase 1/2 Completed